This competitive renewal application for a Specialized Program of Research Excellence (SPORE) in Cervical Cancer at the Johns Hopkins University School of Medicine, University of Alabama at Birmingham and University of Colorado brings together a highly interactive, multidisciplinary, and inter-institutional program of translational research in cervical cancer. The SPORE includes four integrated projects spanning the fields of prevention and treatment of cervical cancer. Project I: L1 Capsomeres as a Next Generation Preventive HPV Vaccine, led by Robert Garcea, M.D., Richard Roden, Ph.D., and Warner Huh, M.D. Project II: Development of a Pan-Oncogenic HPV Preventive Vaccine, led by Richard Roden, Ph.D., and Warner Huh, M.D. Project III;A phase I clinical trial to assess the immunogenicity, safety, tolerability and efficacy of HPV DNA-Vaccinia prime booster vaccination with locally applied TLR agonists in patients with HPV-16+ cervical intraepithelial neoplasia 3 (CIN3), led by Cornelia Trimble, M.D., Drew Pardoll, M.D., Ph.D. and T.-C. Wu, M.D., Ph.D. Project IV: A phase I clinical trial to assess the safety and immunogenicity of repeated, cluster particle-mediated epidermal delivery (PMED) of the DNA vaccine, pNGVL4a-CRT-E7(detox), in patients with operable Stage IB1 cervical cancer associated with HPV-16, led by Ronald Alvarez, M.D., Connie Trimble, M.D. and T.-C. Wu, M.D., Ph.D. These four projects are supported by four Cores that provide critical and supportive infrastructure essential to efficient and effective translational research. The Administration/ Communication Core (Core A) led by T. C. Wu, M.D., Ph.D. and Edward Partridge, M.D, the Biostatistics/ Data Management Core (Core B) led by Mei-Cheng Wang, Ph.D., and Sreelatha Meleth, Ph.D., the Tissue /Pathology Core (Core C) led by Brigitte Ronnett, M.D. and Lawrence Lamb, Ph.D. and the Immunology Core (Core D) led by Raphael Viscidi, M.D. and Chien-Fu Hung, Ph.D. The SPORE also includes a Developmental Research Program for rapid funding of novel research ideas and a Career Development Program to facilitate career development of individuals with interest in translational cervical cancer research.
The intent of our program is to reduce the incidence of cervical cancer and to improve the outcome in patients with HPV associated cervical cancer and their precursor lesions by developing innovative vaccination strategies for the prevention and treatment of cervical cancer.
|Yang, Andrew; Farmer, Emily; Lin, John et al. (2016) The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res :|
|Yang, Andrew; Farmer, Emily; Wu, T C et al. (2016) Perspectives for therapeutic HPV vaccine development. J Biomed Sci 23:75|
|Khan, Michelle J; Massad, L Stewart; Kinney, Walter et al. (2016) A common clinical dilemma: Management of abnormal vaginal cytology and human papillomavirus test results. Gynecol Oncol 141:364-70|
|Khan, Michelle J; Massad, L Stewart; Kinney, Walter et al. (2016) A Common Clinical Dilemma: Management of Abnormal Vaginal Cytology and Human Papillomavirus Test Results. J Low Genit Tract Dis 20:119-25|
|Jiang, Rosie T; Schellenbacher, Christina; Chackerian, Bryce et al. (2016) Progress and prospects for L2-based human papillomavirus vaccines. Expert Rev Vaccines 15:853-62|
|Wang, Yi-Shu; Chen, Jianfeng; Cui, Fengmei et al. (2016) LKB1 is a DNA damage response protein that regulates cellular sensitivity to PARP inhibitors. Oncotarget :|
|Sun, Yun-Yan; Peng, Shiwen; Han, Liping et al. (2016) Local HPV Recombinant Vaccinia Boost Following Priming with an HPV DNA Vaccine Enhances Local HPV-Specific CD8+ T-cell-Mediated Tumor Control in the Genital Tract. Clin Cancer Res 22:657-69|
|Jones, Jacqueline; Mukherjee, Angana; Karanam, Balasubramanyam et al. (2016) African Americans with pancreatic ductal adenocarcinoma exhibit gender differences in Kaiso expression. Cancer Lett 380:513-22|
|Randles, Leah; Anchoori, Ravi K; Roden, Richard B S et al. (2016) The Proteasome Ubiquitin Receptor hRpn13 and Its Interacting Deubiquitinating Enzyme Uch37 Are Required for Proper Cell Cycle Progression. J Biol Chem 291:8773-83|
|Yang, Andrew; Jeang, Jessica; Cheng, Kevin et al. (2016) Current state in the development of candidate therapeutic HPV vaccines. Expert Rev Vaccines 15:989-1007|
Showing the most recent 10 out of 251 publications